ClinicalTrials.gg
Not yet recruitingNCT07923578Updated Nov 6, 2026

Pharmacokinetics, Safety and Tolerability of Single Sequential and Multiple Intravenous Infusions of Ulinastatin for Injection in Healthy Chinese Participants

A Phase 1 interventional study of Ulinastatin and Placebo in Healthy Participants and Ulinastatin, sponsored by Techpool Bio-Pharma Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Techpool Bio-Pharma Co., Ltd. (part of Shanghai Pharmaceuticals Holding Co., Ltd) · Phase 1, Interventional, and Basic science

Updated Nov 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1 clinical study. The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of ulinastatin for injection after single sequential and multiple continuous intravenous infusions in healthy Chinese volunteers.

Key study questions:

  • - How does ulinastatin behave in the body after single sequential and multiple continuous intravenous infusions?
  • - What are the safety outcomes and side effects in healthy people receiving this investigational drug?
  • Study participants will:
  • - Complete screening assessments to check if they meet the study requirements.
  • - Receive either ulinastatin for injection or placebo (inactive substance with no study drug) via intravenous drip.
  • - Follow the study schedule for single sequential infusions and multiple continuous infusions.
  • - Provide blood samples to measure drug concentration in the body.
  • - Undergo safety evaluations including physical examinations, vital sign monitoring and laboratory tests throughout the study period.
  • The study will compare data from participants receiving the study drug versus those receiving placebo to assess drug-related exposure and adverse reactions.
Read the detailed description

This is a single-center, randomized, double-blind, placebo-controlled Phase 1 study of ulinastatin for injection in healthy Chinese adults. Approximately 40 participants will be enrolled sequentially into 4 cohorts and randomized 8:2 to ulinastatin or placebo, to evaluate single ascending doses of 100,000 to 8,000,000 units and multiple ascending doses of 400,000 or 1,600,000 units administered three times daily for 4 consecutive days. Serial blood samples will be collected for non-compartmental pharmacokinetic analysis, and safety and tolerability will be assessed throughout the study.

02

Conditions studied

  • Healthy Participants
  • Ulinastatin
03

In context

Lead sponsor

Techpool Bio-Pharma Co., Ltd. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

First submitted after Techpool Bio-Pharma Co., Ltd. became part of Shanghai Pharmaceuticals Holding Co., Ltd.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be enrolled:

  1. Healthy Chinese male or female participants, as confirmed by medical history, physical examination, vital signs, 12-lead , chest X-ray, and laboratory tests at screening.
  2. Age 18 to 55 years, inclusive.
  3. (BMI) 19.0 to 28.0 kg/m2, inclusive; body weight at least 45.0 kg for women and at least 50.0 kg for men.
  4. Able to understand the procedures and methods of the study, willing to comply strictly with the protocol, and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Participants meeting any of the following criteria are not eligible for enrollment:

    1. Smoking more than 5 cigarettes per day within 3 months before screening, or unable to abstain from smoking from 48 hours before dosing through the study period.
    2. Alcohol intake exceeding 14 units per week within 3 months before screening (1 unit = 360 mL of beer, 45 mL of spirits containing 40% alcohol, or 150 mL of wine), or consumption of alcohol-containing products within 48 hours before the first dose, or unable to abstain from alcohol during the study, or a positive blood alcohol test at screening or at admission (Day -2).
    3. History of drug abuse within 6 months before screening.
    4. History or presence of severe cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease.
    5. History of of any organ system within 5 years before screening, whether treated or untreated, and regardless of evidence of local recurrence or .
    6. History of electrocardiographic abnormalities.
    7. History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurologic disorders that may alter the absorption, metabolism, or elimination of drugs.
    8. Clinically significant abnormalities in laboratory tests at screening.
    9. History or evidence of renal impairment, manifested as clinically significant abnormalities in creatinine, blood urea nitrogen, or urea, or abnormal urine composition (e.g., proteinuria).
    10. Severe illness, severe infection, or trauma within 2 weeks before dosing.
    11. Blood donation of 400 mL or more within 3 months before dosing, or significant blood loss of at least 400 mL.
    12. Allergic constitution, history of drug or food allergy, or known to the study drug or to components of similar drugs.
    13. Participation in any other clinical trial and receipt of an drug or device within 3 months before dosing.
    14. Use of prescription drugs, over-the-counter drugs, herbal medicines, or food supplements (including vitamins), or any drug that may interfere with the interpretation of safety data, or any drug or herbal medicine with known common toxicity to major organs, within 2 weeks before dosing.
    15. Surgery within 3 months before the first dose, or planned surgery during the study period.
    16. Pregnant or lactating women, or men or women of who are unwilling to use effective from the start of the study through 90 days after dosing.
    17. Positive test for surface antigen, virus antibody, (HIV) antibody, or Treponema pallidum antibody.
    18. Difficulty with intravenous administration or blood sampling, or history of needle phobia or hematophobia.
    19. Any other condition that, in the opinion of the investigator, may prevent the participant from completing the study or may place the participant at significant risk.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Ulinastatin single ascending dose (100,000, 2,000,000, and 6,000,000 units)

    Participants receive a single 2-hour intravenous infusion of ulinastatin 100,000 units on Day 1, 2,000,000 units on Day 4, and 6,000,000 units on Day 7.

    Drug: Ulinastatin

  • Placebo comparator
    Cohort 1: Placebo

    Participants receive a single 2-hour intravenous infusion of placebo (5% glucose injection) on Days 1, 4, and 7, matching the ulinastatin schedule in Cohort 1.

    Drug: Placebo

  • Experimental
    Cohort 2: Ulinastatin single ascending dose (1,000,000, 4,000,000, and 8,000,000 units)

    Participants receive a single 2-hour intravenous infusion of ulinastatin 1,000,000 units on Day 1, 4,000,000 units on Day 4, and 8,000,000 units on Day 7.

    Drug: Ulinastatin

  • Placebo comparator
    Cohort 2: Placebo

    Participants receive a single 2-hour intravenous infusion of placebo (5% glucose injection) on Days 1, 4, and 7, matching the ulinastatin schedule in Cohort 2.

    Drug: Placebo

  • Experimental
    Cohort 3: Ulinastatin multiple ascending dose (400,000 units three times daily for 4 days)

    Participants receive 2-hour intravenous infusions of ulinastatin 400,000 units three times daily (at 8:00, 16:00, and 23:00, ±1 hour) on Days 1 to 3, and one morning dose on Day 4 (last dose).

    Drug: Ulinastatin

  • Placebo comparator
    Cohort 3: Placebo

    Participants receive infusions of placebo (5% glucose injection) three times daily on Days 1 to 3 and one morning dose on Day 4, matching the ulinastatin schedule in Cohort 3.

    Drug: Placebo

  • Experimental
    Cohort 4: Ulinastatin multiple ascending dose (1,600,000 units three times daily for 4 days)

    Participants receive 2-hour intravenous infusions of ulinastatin 1,600,000 units three times daily (at 8:00, 16:00, and 23:00, ±1 hour) on Days 1 to 3, and one morning dose on Day 4 (last dose).

    Drug: Ulinastatin

  • Placebo comparator
    Cohort 4: Placebo

    Participants receive infusions of placebo (5% glucose injection) three times daily on Days 1 to 3 and one morning dose on Day 4, matching the ulinastatin schedule in Cohort 4.

    Drug: Placebo

Interventions

  • Name Ulinastatin for injection Type Drug Other Names Ulinastatin; UTI Lyophilized powder for injection, 100,000 units per vial; white to slightly yellow lyophilized cake or powder. Reconstituted and diluted in 250 mL of 5% glucose injection, then administered by intravenous infusion over 2 hours (±5 minutes). Single doses of 100,000 to 8,000,000 units were administered in the single-ascending-dose cohorts; doses of 400,000 or 1,600,000 units were administered three times daily for 4 consecutive days in the multiple-ascending-dose cohorts. Manufactured by Guangdong Techpool Biochemical Pharmaceutical Co., Ltd.

  • DrugPlacebo

    Name Placebo Type Drug Other Names 5% glucose injection 250 mL of 5% glucose injection, prepared and administered so as to be indistinguishable in appearance from the reconstituted study drug. Contains no active ingredient.

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration(Cmax)

    Descriptive statistics by dose level; non-compartmental analysis.Blood samples were also collected at matching time points on Day -1 (baseline) for endogenous baseline correction.

    Time frame: Up to 24 hours after the start of each infusion on Days 1, 4, and 7

  2. Area under the plasma concentration-time curve from time zero to the last quantifiable

    Descriptive statistics by dose level; non-compartmental analysis.Blood samples were also collected at matching time points on Day -1 (baseline) for endogenous baseline correction.

    Time frame: Up to 24 hours after the start of each infusion on Days 1, 4, and 7

  3. Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf)

    Descriptive statistics by dose level; non-compartmental analysis.Blood samples were also collected at matching time points on Day -1 (baseline) for endogenous baseline correction.

    Time frame: Up to 24 hours after the start of each infusion on Days 1, 4, and 7

  4. Time to reach peak plasma concentration (Tmax)

    Descriptive statistics by dose level; non-compartmental analysis.Blood samples were also collected at matching time points on Day -1 (baseline) for endogenous baseline correction.

    Time frame: Up to 24 hours after the start of each infusion on Days 1, 4, and 7

  5. Terminal elimination half-life (t1/2)

    Time frame: Up to 24 hours after the start of each infusion on Days 1, 4, and 7

  6. Apparent clearance (CL)

    Time frame: Up to 24 hours after the start of each infusion on Days 1, 4, and 7

  7. Apparent volume of distribution (Vz)

    Time frame: Up to 24 hours after the start of each infusion on Days 1, 4, and 7

  8. Peak plasma concentration at steady state (Cmax,ss)

    Time frame: Up to 24 hours after the start of the Day 4 infusion (last dose)

  9. Trough plasma concentration at steady state (Cmin,ss)

    Time frame: Predose on Day 4

  10. Time to reach peak plasma concentration at steady state (Tmax,ss)

    Time frame: Up to 24 hours after the start of the Day 4 infusion (last dose)

  11. Area under the plasma concentration-time curve during a dosing interval at steady state (AUC0-tau,ss)

    Time frame: Up to 24 hours after the start of the Day 4 infusion (last dose)

  12. Accumulation ratio based on Cmax and AUC0-tau (Rac)

    Time frame: Up to 24 hours after the start of the Day 4 infusion (last dose)

Secondary outcomes

  1. Incidence and severity of adverse events (AEs)

    Time frame: From the first dose up to 7 days (±1 day) after the last dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared. The data are proprietary to the sponsor and are not made available to external parties.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2026
First posted
Nov 6, 2026
StartEst.
Nov 2026
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07923578
Responsible party
Sponsor
First posted
Nov 6, 2026
Start date
Nov 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Mingjuan Hua
Contact
huamj@techpool.com.cn
+86-20-38972288

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Urinastatin

Start the discussion